Antibodies that specifically bind to tl5
CA 2481401 A1 · Owner: Ruben, Steven M. · Inventors: Ruben, Steven M.; Rosen, Craig A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses for example, in the , prevention and treatment of cancer as well as immune system diseases and disorders including autoimmune disease rheumatoid arthritis, graft rejection, graft vs. host disease and lymphadenopathy. The invention also relates to nucleic acid molecules encoding anti~TL5 antibodies vectors and host cells , containing these nucleic acids and methods for producing the same. The present invention relates to methods and compositions for preventing detecting, diagnosing, treating or ameliorating a disease or disorder especially cancer as well as immune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 10, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 10, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 10, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.